Back to Search
Start Over
Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
- Source :
- Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
- Publication Year :
- 2021
- Publisher :
- SAGE Publishing, 2021.
-
Abstract
- Background: A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (ALSFRS-R) progression rate from disease onset to baseline of
- Subjects :
- Neurology. Diseases of the nervous system
RC346-429
Subjects
Details
- Language :
- English
- ISSN :
- 17562864
- Volume :
- 14
- Database :
- Directory of Open Access Journals
- Journal :
- Therapeutic Advances in Neurological Disorders
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.f78aa62ba2b0457d8e5fbdaa8ef19004
- Document Type :
- article
- Full Text :
- https://doi.org/10.1177/17562864211030365